Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

High levels of anti-SSA/Ro antibodies in COVID-19 patients with severe respiratory failure : a case-based review : High levels of anti-SSA/Ro antibodies in COVID-19

We treated two patients with severe respiratory failure due to coronavirus disease 2019 (COVID-19). Case 1 was a 73-year-old woman, and Case 2 was a 65-year-old-man. Neither of them had a history of autoimmune disease. Chest computed tomography scans before the antiviral therapy showed bilateral multiple patchy ground-glass opacities (GGO) consistent with COVID-19 pneumonia. The GGO regressed over the course of the antiviral treatment; however, new non-segmental patchy consolidations emerged, which resembled those of interstitial lung disease (ILD), specifically collagen vascular disease-associated ILD. We tested the patients' sera for autoantibodies and discovered that both patients had high anti-SSA/Ro antibody titers. In Case 1, the patient recovered with antiviral therapy alone. However, in Case 2, the patient did not improve with antiviral therapy alone but responded well to corticosteroid therapy (methylprednisolone) and made a full recovery. The relationship between some immunological responses and COVID-19 pneumonia exacerbation has been discussed previously; our discovery of the elevation of anti-SSA/Ro antibodies suggests a contribution from autoimmunity functions of the immune system. Although it is unclear whether the elevation of anti-SSA/Ro antibodies was a cause or an outcome of aggravated COVID-19 pneumonia, we hypothesize that both patients developed aggravated the COVID-19 pneumonia due to an autoimmune response. In COVID-19 lung injury, there may be a presence of autoimmunity factors in addition to the known effects of cytokine storms. In patients with COVID-19, a high level of anti-SSA/Ro52 antibodies may be a surrogate marker of pneumonia severity and poor prognosis

Year of Publication: 2020
Contained in: Clinical rheumatology Vol. 39, No. 11 (2020), p. 3171-3175
All journal articles: Search for all articles in this journal
Language: English
Contributors: Fujii, Hiroyuki | Author
Tsuji, Taisuke
Yuba, Tatsuya
Tanaka, Shunya
Suga, Yoshifumi
Matsuyama, Aosa
Omura, Ayaka
Shiotsu, Shinsuke
Takumi, Chieko
Ono, Seiko
Horiguchi, Masahito
Hiraoka, Noriya
Full text access:
Electronic availability is being checked...
Links: Full Text (dx.doi.org)
Keywords: 4QWG6N8QKH
Anti-SSA/Ro antibodies
Case Reports
Coronavirus disease 2019 (COVID-19)
Corticosteroid
EW5GL2X7E0
Journal Article
Review
S59502J185
SS-A antibodies
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
X4W7ZR7023
Y25LQ0H97D
ciclesonide
favipiravir
nafamostat
Additional Keywords: Aged
Amides
Antibodies, Antinuclear
Antiviral Agents
Betacoronavirus
Coronavirus Infections
Female
Glucocorticoids
Guanidines
Humans
Hydroxychloroquine
Lung Diseases, Interstitial
Male
Methylprednisolone
Pandemics
Pneumonia, Viral
Pregnenediones
Pyrazines
Recovery of Function
Respiratory Distress Syndrome, Adult
Respiratory Insufficiency
Severity of Illness Index
Tomography, X-Ray Computed
ISSN: 1434-9949
Note: Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Notes: Date Completed 23.10.2020
Date Revised 23.10.2020
published: Print-Electronic
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PMID:
    32844364
Physical Description: Online-Ressource
ID (e.g. DOI, URN): 10.1007/s10067-020-05359-y
more publication details ...

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 06681nma a2201357 c 4500
001 NLM31511911X
003 DE-601
005 20201024213531.0
007 cr uuu---uuuuu
008 200826s2020 000 0 eng d
024 7 |a 10.1007/s10067-020-05359-y  |2 doi 
028 5 2 |a pubmed20n1443.xml 
035 |a (DE-599)NLM32844364 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Fujii, Hiroyuki 
245 1 0 |a High levels of anti-SSA/Ro antibodies in COVID-19 patients with severe respiratory failure  |h Elektronische Ressource  |b a case-based review : High levels of anti-SSA/Ro antibodies in COVID-19 
300 |a Online-Ressource 
500 |a Date Completed 23.10.2020 
500 |a Date Revised 23.10.2020 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a We treated two patients with severe respiratory failure due to coronavirus disease 2019 (COVID-19). Case 1 was a 73-year-old woman, and Case 2 was a 65-year-old-man. Neither of them had a history of autoimmune disease. Chest computed tomography scans before the antiviral therapy showed bilateral multiple patchy ground-glass opacities (GGO) consistent with COVID-19 pneumonia. The GGO regressed over the course of the antiviral treatment; however, new non-segmental patchy consolidations emerged, which resembled those of interstitial lung disease (ILD), specifically collagen vascular disease-associated ILD. We tested the patients' sera for autoantibodies and discovered that both patients had high anti-SSA/Ro antibody titers. In Case 1, the patient recovered with antiviral therapy alone. However, in Case 2, the patient did not improve with antiviral therapy alone but responded well to corticosteroid therapy (methylprednisolone) and made a full recovery. The relationship between some immunological responses and COVID-19 pneumonia exacerbation has been discussed previously; our discovery of the elevation of anti-SSA/Ro antibodies suggests a contribution from autoimmunity functions of the immune system. Although it is unclear whether the elevation of anti-SSA/Ro antibodies was a cause or an outcome of aggravated COVID-19 pneumonia, we hypothesize that both patients developed aggravated the COVID-19 pneumonia due to an autoimmune response. In COVID-19 lung injury, there may be a presence of autoimmunity factors in addition to the known effects of cytokine storms. In patients with COVID-19, a high level of anti-SSA/Ro52 antibodies may be a surrogate marker of pneumonia severity and poor prognosis 
611 2 7 |a Case Reports  |2 gnd 
611 2 7 |a Journal Article  |2 gnd 
611 2 7 |a Review  |2 gnd 
653 2 |a Aged  |6 D000368 
653 2 |a Amides  |6 D000577  |a therapeutic use  |6 Q000627 
653 2 |a Antibodies, Antinuclear  |6 D000974  |a *immunology  |6 Q000276 
653 2 |a Antiviral Agents  |6 D000998  |a therapeutic use  |6 Q000627 
653 2 |a Betacoronavirus  |6 D000073640 
653 2 |a Coronavirus Infections  |6 D018352  |a complications  |6 Q000150  |a diagnostic imaging  |6 Q000000981  |a drug therapy  |6 Q000188  |a *immunology  |6 Q000276 
653 2 |a Female  |6 D005260 
653 2 |a Glucocorticoids  |6 D005938  |a therapeutic use  |6 Q000627 
653 2 |a Guanidines  |6 D006146  |a therapeutic use  |6 Q000627 
653 2 |a Humans  |6 D006801 
653 2 |a Hydroxychloroquine  |6 D006886  |a therapeutic use  |6 Q000627 
653 2 |a Lung Diseases, Interstitial  |6 D017563  |a diagnostic imaging  |6 Q000000981  |a drug therapy  |6 Q000188  |a etiology  |6 Q000209  |a *immunology  |6 Q000276 
653 2 |a Male  |6 D008297 
653 2 |a Methylprednisolone  |6 D008775  |a therapeutic use  |6 Q000627 
653 2 |a Pandemics  |6 D058873 
653 2 |a Pneumonia, Viral  |6 D011024  |a complications  |6 Q000150  |a diagnostic imaging  |6 Q000000981  |a drug therapy  |6 Q000188  |a *immunology  |6 Q000276 
653 2 |a Pregnenediones  |6 D011282  |a therapeutic use  |6 Q000627 
653 2 |a Pyrazines  |6 D011719  |a therapeutic use  |6 Q000627 
653 2 |a Recovery of Function  |6 D020127 
653 2 |a Respiratory Distress Syndrome, Adult  |6 D012128  |a etiology  |6 Q000209  |a immunology  |6 Q000276 
653 2 |a Respiratory Insufficiency  |6 D012131  |a etiology  |6 Q000209  |a *immunology  |6 Q000276 
653 2 |a Severity of Illness Index  |6 D012720 
653 2 |a Tomography, X-Ray Computed  |6 D014057 
655 7 |a Anti-SSA/Ro antibodies  |2 gnd 
655 7 |a Coronavirus disease 2019 (COVID-19)  |2 gnd 
655 7 |a Corticosteroid  |2 gnd 
655 7 |a Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)  |2 gnd 
655 7 |a Amides  |2 gnd 
655 7 |a Antibodies, Antinuclear  |2 gnd 
655 7 |a Antiviral Agents  |2 gnd 
655 7 |a Glucocorticoids  |2 gnd 
655 7 |a Guanidines  |2 gnd 
655 7 |a Pregnenediones  |2 gnd 
655 7 |a Pyrazines  |2 gnd 
655 7 |a SS-A antibodies  |2 gnd 
655 7 |a Hydroxychloroquine  |2 gnd 
655 7 |a 4QWG6N8QKH  |2 gnd 
655 7 |a favipiravir  |2 gnd 
655 7 |a EW5GL2X7E0  |2 gnd 
655 7 |a ciclesonide  |2 gnd 
655 7 |a S59502J185  |2 gnd 
655 7 |a Methylprednisolone  |2 gnd 
655 7 |a X4W7ZR7023  |2 gnd 
655 7 |a nafamostat  |2 gnd 
655 7 |a Y25LQ0H97D  |2 gnd 
689 0 0 |A f  |a Case Reports 
689 0 1 |A f  |a Journal Article 
689 0 2 |A f  |a Review 
689 0 |5 DE-601 
689 1 0 |a Anti-SSA/Ro antibodies 
689 1 1 |a Coronavirus disease 2019 (COVID-19) 
689 1 2 |a Corticosteroid 
689 1 3 |a Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
689 1 |5 DE-601 
689 2 0 |a Amides 
689 2 1 |a Antibodies, Antinuclear 
689 2 2 |a Antiviral Agents 
689 2 3 |a Glucocorticoids 
689 2 4 |a Guanidines 
689 2 5 |a Pregnenediones 
689 2 6 |a Pyrazines 
689 2 7 |a SS-A antibodies 
689 2 8 |a Hydroxychloroquine 
689 2 9 |A r  |a 4QWG6N8QKH 
689 2 X |a favipiravir 
689 2 X |A r  |a EW5GL2X7E0 
689 2 X |a ciclesonide 
689 2 X |A r  |a S59502J185 
689 2 X |a Methylprednisolone 
689 2 X |A r  |a X4W7ZR7023 
689 2 X |a nafamostat 
689 2 X |A r  |a Y25LQ0H97D 
689 2 |5 DE-601 
700 1 |a Tsuji, Taisuke 
700 1 |a Yuba, Tatsuya 
700 1 |a Tanaka, Shunya 
700 1 |a Suga, Yoshifumi 
700 1 |a Matsuyama, Aosa 
700 1 |a Omura, Ayaka 
700 1 |a Shiotsu, Shinsuke 
700 1 |a Takumi, Chieko 
700 1 |a Ono, Seiko 
700 1 |a Horiguchi, Masahito 
700 1 |a Hiraoka, Noriya 
773 0 8 |i in  |t Clinical rheumatology  |g Vol. 39, No. 11 (2020), p. 3171-3175  |q 39:11<3171-3175  |w (DE-601)NLM012613126  |x 1434-9949 
856 4 1 |u http://dx.doi.org/10.1007/s10067-020-05359-y  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |d 39  |j 2020  |e 11  |b 23  |c 10  |h 3171-3175